{"name":"Natera","slug":"natera","ticker":"NTRA","exchange":"NASDAQ","domain":"natera.com","description":"Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.","hq":"Austin, TX","founded":2004,"employees":"6135","ceo":"Steve Chapman","sector":"Molecular Diagnostics / Genomics","stockPrice":212.55,"stockChange":3.28,"stockChangePercent":1.57,"marketCap":"$30.1B","metrics":{"revenue":2306113024,"revenueGrowth":39.8,"grossMargin":64.7,"rdSpend":0,"netIncome":-208160000,"cash":1076140032,"dividendYield":0,"peRatio":-300.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Natera Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Natera reported fourth quarter and full year 2023 financial results, with revenue of $244.8 million and a net loss of $44.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-07","type":"deal","headline":"Natera Announces Collaboration with Illumina to Develop Next-Generation Non-Invasive Prenatal Testing (NIPT) Products","summary":"Natera announced a collaboration with Illumina to develop next-generation NIPT products, expanding the company's presence in the prenatal testing market.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Clears Natera's Signatera Liquid Biopsy Test for Use in Monitoring Colorectal Cancer","summary":"The FDA cleared Natera's Signatera liquid biopsy test for use in monitoring colorectal cancer, expanding the test's indications.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"trial","source":"simplywall.st","summary":"Assessing Natera (NTRA) Valuation After New Signatera Breast Cancer Study Results - simplywall.st","headline":"Assessing Natera (NTRA) Valuation After New Signatera Breast Cancer Study Results","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Natera (NTRA) After Its Recent Share Price Pullback - simplywall.st","headline":"Is It Time To Reassess Natera (NTRA) After Its Recent Share Price Pullback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPNmY0SUFQVVlUU3o1bVNrbVctVGhWdDFmRUlyOHVvNld3Y3lCU3RqZnBiWFhhRkFIc3Z6WjM4V1lLN3Z5Z1Y5UnVYMjBKc0lnLVRNc0RDSTItcTBjMUlZamNfVmIwY1NlZ05MampwdzByTmdiRWtaQ2NCQ0RNb1ZWMzdRZzU3MU5HSS1KOFJ0aXNTYm9ud3FUdmlodE9DZw?oc=5","date":"2026-03-16","type":"pipeline","source":"Yahoo Finance","summary":"NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance","headline":"NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPbHhkUWxWeHE3cW9jbndiQUZNeEVqd004bkxqSmdZY2lFM01NMmlsa0ZCZkRaeGIzSzdoaHJPalVZQm5VcDJLN1h2OTl4RGNUSVhzQ3Z1QnVJT3p2MEttYVhtUmo3TXp3RFJtRmgxa3V6bWlvY2NURlc4cHNwdlpGSTVRbU1xT2JIWVJob2Vtaw?oc=5","date":"2026-02-05","type":"pipeline","source":"The Motley Fool","summary":"Best Genomics Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool","headline":"Best Genomics Stocks of 2026: Are They Right for Your Portfolio?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNcjZrdDBnOXVsd2RmdlFjY0hGUGVQbEkxbEZjY3BaMVl1MXRxY1M0cGpTQXpuNXpMNjhoR1hfQ0kzQk5RU3pGQlFXV1lrcnFSQUdhQ09JRXNmSkZkY0Z1UjdFSzktb1N2ekZmVkxVR01qQmhHdjJXQ2U1YmJibGd4cGpkbVNCVFR0Z1AyYmczUHA4Y2ppb2c2cEFEeXRYcjRJcVd4SlhKSE9CZTV1VTNZVHJIdkJSNUJGcTFXc1ZZSjl6MVVfWGV3eVlmc2hoaEZNZmpzV09kVUJZTW5CYjM4MDF2U2piZ3REUUE?oc=5","date":"2026-01-25","type":"pipeline","source":"The Globe and Mail","summary":"2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds - The Globe and Mail","headline":"2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPMkZVQV9nS1pLelRUOC1Za0Z6OS1tVWpiR3JxZjRNOUtEbi03Rmp0a2FSMVRkVVVQOTF2Y3J5Y2dYekFIcEJTUGljRUxodVk5RVlkdm5LNFZTaVo5WHBCdmhfLXl5dGFOdFVqSzF6eFRFSFBTS3B6NUFRSWx2OVo3SVNydU9EUEliRURNWnBjT0g?oc=5","date":"2025-12-11","type":"pipeline","source":"AOL.com","summary":"Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks - AOL.com","headline":"Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPR3REQThjaGpIeDk1bkNQS0tOclFRMkpTY0NLaGtSYTRVbzBfa3ZKRkdkZkRMQjR1UVlQUmdxRFRRZVh4emFMNFEyWlA1SFNzcjVwUkZpZUh2LUdidVJmRG85RU1vbjRySmdQeW9xSnJoQ01fNS1QSEUzUHpNdjFIM05ENTJmOTRhcFpsTXFFNFJ5MHJCQVdyemduMTRDQUcyYl85NEJ2Vjl3NE9BRnZQQ3lUOA?oc=5","date":"2025-11-30","type":"regulatory","source":"Seeking Alpha","summary":"Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins - Seeking Alpha","headline":"Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTzViRWI5X29xMjBuX0RjUjVYQTJCQnIzeDVmNEl5ZWZuSWhReE1uYkVqNkpEYW5pZG9faTAxUUhxcFJ0T25BWEpzdDVqUFBGMjJoWGtwVENHTmVBR0hzRGswb29iLUdIdGNHaEQ4NVFlbG5rS0tmMXNvYlNjdzFEV2hMNnhvc0JqandRdjNhSGd3ejQ0NUF4NVktVFNsVE1Qa3A4c1N0NkE1Rlc3V19uRkItem9lSWUxTVVr?oc=5","date":"2025-11-30","type":"pipeline","source":"Finviz","summary":"30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz","headline":"30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQamVETWxRRTBwdFJCd1VlR3lwWm5PREk5VXFhVDNCcnZTeGNrMEVBVzdMeWtrd0cwUDNzWGI5MmdKalRkRnlyMDBKOFA5dXJaM1h1eEozMU04eElNUzNvbnUyLXJYc09IM09heEFBNTM1b0pQdUwyVG9YWUx5TmNkQzJyeF9xSGs3WERCOHh3c3FnSnlCcDRYaDd4ZzlrNVBFRUdOMzZsRWpwb2VmY21qQTBZcWRpWVhlZXktV2RlMno1U0JLQ3BaNlJnSW5EUE1Zd3pvRWpPRQ?oc=5","date":"2025-11-24","type":"deal","source":"24/7 Wall St.","summary":"This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now. - 24/7 Wall St.","headline":"This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now. - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOLU9qNWZSQlNuYW81S1NaU2wtVnlUdm1TYUxWcXFhYjByc0Z0eFdFakIxMmRzT1RJM1dPOFZHYjVBNTVQaFNYZU1oRmd5QmhId0VuYkdjYThzR2hJYnZDbDhsekpGRVk3Z0wzU2liSy01dGEzUGt0R2RyaG81MG4tS3c1SldkWFY2YllwQkN6c3FnajQwRW1R?oc=5","date":"2025-09-19","type":"deal","source":"TIKR.com","summary":"Stanley Druckenmiller’s Portfolio: 5 of the Best Stocks to Buy Today - TIKR.com","headline":"Stanley Druckenmiller’s Portfolio: 5 of the Best Stocks to Buy Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE43QXFCeGVmNmFZZlRSdkV3SVdwNmVkMUVOOW90NHNjeW4yZXpQNVV0WDdxMFhXTUxMS1g4LXBsa2R5NTlhLTZCZjM0VFJhWm4xZi1WM1BKa1ZNNXpIRjdIc1h3UGRGUENjNW9PNXpEbU9iRG9vSWVoYUROMjhyNzA?oc=5","date":"2025-08-25","type":"pipeline","source":"Yahoo Finance","summary":"Natera Shares Rise on the Launch of AI Platform for Precision Oncology - Yahoo Finance","headline":"Natera Shares Rise on the Launch of AI Platform for Precision Oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOTmx3N0FiSHJHeHotUUhwMXBHUFJ4WnpUT0w4anlJT0NrSUJfRmxEUUdrd0dyaHNiQ0N1cFhlZmVEZW5kenhPTmpWQTA0WnZ5cEpTbHpzUVFfam5tb2pyT1VmZjAzSktBTjBFd0JPRkhBVzRyc29VaHNvNWNudTlMYmtYOFNaSmZjWDJEMGpVVS1CTmkxMHVoeGFlcXVGZXlPdmRwYkpTVGotTm1q?oc=5","date":"2025-07-27","type":"deal","source":"The Acquirer's Multiple","summary":"Stanley Druckenmiller’s Top 5 Positions Make Up 42.14% Of His Portfolio - The Acquirer's Multiple","headline":"Stanley Druckenmiller’s Top 5 Positions Make Up 42.14% Of His Portfolio - The Acquirer's Multiple","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Exact Sciences","Invitae","Foundation Medicine"],"therapeuticFocus":["Oncology","Genetic Disorders"],"financials":null,"yahoo":{"currentPrice":212.55,"previousClose":209.27,"fiftyTwoWeekHigh":256.36,"fiftyTwoWeekLow":130.29,"fiftyTwoWeekRange":"130.29 - 256.36","fiftyDayAverage":207.9,"twoHundredDayAverage":192.86,"beta":1.68,"enterpriseValue":28798334976,"forwardPE":-300.1,"priceToBook":17.34,"priceToSales":13.06,"enterpriseToRevenue":12.49,"enterpriseToEbitda":-106.1,"pegRatio":0,"ebitda":-271427008,"ebitdaMargin":-11.8,"freeCashflow":141016496,"operatingCashflow":215300992,"totalDebt":214376992,"debtToEquity":12.5,"currentRatio":3.39,"returnOnAssets":-9.5,"returnOnEquity":-14.3,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":19,"targetMeanPrice":258.58,"targetHighPrice":300,"targetLowPrice":190,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3,"institutionHeldPercent":94.5,"sharesOutstanding":141731250,"floatShares":137472226,"sharesShort":3306015,"shortRatio":2.76,"shortPercentOfFloat":2.3,"epsTrailing":-1.53,"epsForward":-0.71,"revenuePerShare":16.87,"bookValue":12.26,"officers":[{"age":52,"name":"Dr. Matthew  Rabinowitz Ph.D.","title":"Co-Founder & Executive Chairman"},{"age":46,"name":"Mr. Steven Leonard Chapman","title":"CEO & Director"},{"age":46,"name":"Mr. John  Fesko","title":"President & Chief Business Officer"},{"age":45,"name":"Mr. Michael B. Brophy M.B.A.","title":"Chief Financial Officer"},{"age":42,"name":"Mr. Solomon  Moshkevich M.B.A.","title":"President of Clinical Diagnostics"},{"age":52,"name":"Mr. Jonathan  Sheena M.Eng.","title":"Co-Founder & Director"},{"age":null,"name":"Ms. Olesya A. Anisimova CPA","title":"Chief Accounting Officer"},{"age":null,"name":"Mr. Rishi  Kacker","title":"Chief Technology Officer"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.natera.com","phone":"650 980 9190"}}